Trials on ICS-283 will begin in 2008.

Intradigm chose Agilent Technologies to manufacture the active siRNA component of its RNAi therapeutic. In addition, Intradigm selected ICS-283 as its lead RNAi product candidate.


Under terms of the agreement, Agilent will support the initiation of clinical development for ICS-283. Intradigm expects to initiate trials in 2008.


ICS-283 is the only systemic RNAi therapeutic in preclinical development against a clinically validated oncology target (vascular endothelial growth factor or VEGF), according to Intradigm. It is a nanoparticle-based compound comprised of multiple siRNAs that target both VEGF and its receptor.

Previous articleGoodwin Biotechnology to Produce Neogenix’ mAb for Pancreatic Cancer
Next articleGenentech to Help Abbott Advance Two Early-Stage Anticancer Compounds